Introduction Pharmaron Beijing Co., Ltd. is a professional company that offers comprehensive drug research, development, and production services. These services encompass all stages of drug discovery, development, and production. The company provides laboratory, CMC, macromolecules and cell & gene therapy, and clinical research services to its clients. Founded by Bo Liang Lou, Xiao Qiang Lou, and Bei Zheng on July 1, 2004, Pharmaron Beijing Co., Ltd. is headquartered in Beijing, China. |
Disease Domain | Count |
---|---|
Neoplasms | 2 |
Nervous System Diseases | 1 |
Immune System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Chemical drugs | 1 |
Synthetic peptide | 1 |
Hormone | 1 |
Biosimilar | 1 |
Target |
Mechanism Sodium channels blockers |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date29 Aug 2008 |
Target |
Mechanism KRAS G12C inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MLLT1 modulators |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date27 Sep 2022 |
Sponsor / Collaborator |
Start Date31 Aug 2022 |
Sponsor / Collaborator |
Start Date21 Aug 2022 |
Sponsor / Collaborator Patheon, Inc. [+2] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Lacosamide ( Sodium channels ) | Epilepsies, Partial More | Approved |
GF-105 ( KRAS G12C ) | KRAS G12C mutant Non-small Cell Lung Cancer More | NDA/BLA |
Follitropin alfa biosimilar(Bridge Pharmaceuticals, Inc.) ( FSHR ) | Infertility, Female More | Phase 3 |
LANA-PL | Hypertension, Pulmonary More | Preclinical |
TDI-11055 ( MLLT1 ) | Adult Acute Myeloblastic Leukemia More | Preclinical |